Zusammenfassung
Mit den klassischen Prognosefaktoren für Kopf-Hals-Karzinome war eine Abschätzung des klinischen Verlaufs möglich, Unterschiede im individuellen Therapieansprechen oder im Verlauf stadiengleicher Tumoren blieben jedoch unscharf charakterisiert. Es mangelte an einer individuellen molekularen Signatur des einzelnen Tumors bzw. Patienten. Trotz zahlreicher Publikationen zu intensiv erforschten neuen Prognose-/Biomarkern orientieren sich die Therapieplanung und Prognoseabschätzung in den meisten Zentren mit wenigen Ausnahmen (z. B. HPV-Status bei Oropharynxkarzinomen) nur an den klassischen Parametern wie Tumorstadium und histologischem Differenzierungsgrad. Die Zukunft wird aber voraussichtlich nicht in Einzelmarkern, sondern in einem Markerprofil liegen, wie es die Microarray-Technologie ermöglicht. In dieser Arbeit werden die Kriterien für einen erfolgreichen Biomarkerkandidaten vermittelt und eine Übersicht über die wichtigsten neuen Biomarker gegeben. Zudem wird das Prinzip genomischer und proteomischer Biomarkerchips vorgestellt.
Abstract
Classical prognostic factors for squamous cell carcinoma of the head and neck (HNSCC) are based on general parameters such as tumor stage or histological grading and only allow for a rough estimation of the clinical course. However, predicting individual responses to treatment remains challenging and diverging clinical courses of same-stage HNSCC stage remain obscure. The need for a better understanding of the individual genomic or proteomic signature of HNSCC resulted in a great number of publications on novel biomarkers. Still, in most cancer centres therapy planning and risk appraisal are solely based on the classical factors with only a few exceptions such as HPV status in oropharyngeal carcinoma. Future improvements in biomarker research will probably be achieved with sets of various genomic and proteomic markers as provided by microarray technology. This review highlights the criteria for a successful biomarker candidate, gives an overview on the most important new biomarkers, and introduces the principles of genomic and proteomic biomarker chips.
Literatur
Bagnardi V, Blangiardo M, La VC, Corrao G (2001) A meta-analysis of alcohol drinking and cancer risk. Br J Cancer 85:1700–1705
Begum S, Gillison ML, Ansari-Lari MA et al (2003) Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res 9:6469–6475
Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578
Chang SS, Califano J (2008) Current status of biomarkers in head and neck cancer. J Surg Oncol 97:640–643
Chung CH, Parker JS, Karaca G et al (2004) Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5:489–500
Cojocariu OM, Huguet F, Lefevre M, Perie S (2009) Prognosis and predictive factors in head-and-neck cancers. Bull Cancer 96:369–378
Fakhry C, Westra WH, Li S et al (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261–269
Geisler SA, Olshan AF, Weissler MC et al (2002) p16 and p53 Protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res 8:3445–3453
Hoffmann TK, Whiteside TL, Bier H (2005) Plattenepithelkarzinome des Kopf-Hals-Bereichs – Grundlagen und aktuelle Konzepte der Immuntherapie. HNO 53: 285–298
Hsu KF, Hung CF, Cheng WF et al (2001) Enhancement of suicidal DNA vaccine potency by linking mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther 8:376–383
Kornberg LJ, Villaret D, Popp M et al (2005) Gene expression profiling in squamous cell carcinoma of the oral cavity shows abnormalities in several signaling pathways. Laryngoscope 115:690–698
Lang S, Zeidler R (2003) Immune restoration in head and neck cancer patients via cyclooxygenase inhibition: an update. Int J Immunopathol Pharmacol 16:41–48
Langendijk JA, Slotman BJ, van der Waal I et al (2005) Risk-group definition by recursive partitioning analysis of patients with squamous cell head and neck carcinoma treated with surgery and postoperative radiotherapy. Cancer 104:1408–1417
Lehnerdt GF, Franz P, Zaqoul A et al (2008) Overall and relapse-free survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene. Clin Cancer Res 14:1753–1758
Pai SI, Westra WH (2009) Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol 4:49–70
Pelucchi C, Gallus S, Garavello W et al (2008) Alcohol and tobacco use, and cancer risk for upper aerodigestive tract and liver. Eur J Cancer Prev 17:340–344
Poeta ML, Manola J, Goldwasser MA et al (2007) TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 357:2552–2561
Ranelletti FO, Almadori G, Rocca B et al (2001) Prognostic significance of cyclooxygenase-2 in laryngeal squamous cell carcinoma. Int J Cancer 95:343–349
Rocco JW, Li D, Liggett WH Jr et al (1998) p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer. Clin Cancer Res 4:1697–1704
Scurry WC Jr, Stack BC Jr (2007) Role of metalloproteins in the clinical management of head and neck squamous cell carcinoma. Head Neck 29:1144–1155
Silva P, Homer JJ, Slevin NJ et al (2007) Clinical and biological factors affecting response to radiotherapy in patients with head and neck cancer: a review. Clin Otolaryngol 32:337–345
Thomas GR, Nadiminti H, Regalado J (2005) Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol 86:347–363
Danksagung
Wir bedanken uns bei Herrn PD Dr. Ludger Klein-Hitpass, Zentrum für Medizinische Biotechnologie, sowie bei Frau Prof. Dr. Agnes Bankfalvi, Institut für Pathologie und Neuropathologie, Universität Duisburg-Essen, für die Überlassung der Genchip- bzw. der P16-Immunhistochemie-Abbildung.
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lehnerdt, G., Hoffmann, T., Mattheis, S. et al. Tumormarker und Prognosefaktoren bei Plattenepithelkarzinomen der Kopf-Hals-Region. HNO 58, 713–725 (2010). https://doi.org/10.1007/s00106-010-2108-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00106-010-2108-8